tbuckley/cabot-search huggingface dataset:
Ileal pneumatosis
Authors: E. Viale, B. Mangiavillano
Journal: Endoscopy (2008)

Intestinal pneumatosis (IP) is a relatively rare, benign condition, described for the first time by Du Vernoi in 1730 [1]. It is characterized by the presence of gas inside the intestinal mucosa, and having an appearance of bunch-like cysts on endoscopy. Intestinal pneumatosis is usually asymptomatic, but may sometimes cause diarrhea, abdominal discomfort or pain, or constipation. Complications associated with intestinal pneumatosis, such as obstruction from volvulus or intussusception, are rare [2].
ERYSIPELAS TOXINS IN THE TREATMENT OF MALIGNANT TUMORS.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Importance of Healing Skills in the Medical Home Concept
Authors: William E. Cayley
Journal: Annals of Internal Medicine (2009)

Letters3 March 2009The Importance of Healing Skills in the Medical Home ConceptWilliam E. Cayley, MD, MDivWilliam E. Cayley, MD, MDivFrom the University of Wisconsin, Milwaukee, WI 53211.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-150-5-200903030-00022 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The healing skills identified by Churchill and Schenck (1) are vital to implementing continuity care “personal care” and a “whole-person orientation,” 2 of the original 4 principles of a medical home described by Rogers (2) (the other 2 principles being team-directed medical practice and care that is coordinated and integrated). More recent iterations of the medical home concept, however, have moved from including reimbursement as a piece of the medical home (3) to translating “medical home” almost exclusively into a reimbursement concept. This article provides helpful documentation of the healing skills that must be the foundation of ...References1. Churchill LR, Schenck D. Healing skills for medical practice. Ann Intern Med. 2008;149:720-4. [PMID: 19017590] LinkGoogle Scholar2. Rogers JC. Assembling patient-centered medical homes—the care principles. Fam Med. 2007;39:697-9. [PMID: 17987408] MedlineGoogle Scholar3. American Academy of Family Physicians, American Academy of Pediatrics, American College of Physicians, American Osteopathic Association. Joint Principles of the Patient-Centered Medical Home. Accessed at www.acponline.org/advocacy/where_we_stand/medical_home/approve_jp.pdf on 20 January 2009. Google Scholar Author, Article, and Disclosure InformationAuthors: William E. Cayley, MD, MDivAffiliations: From the University of Wisconsin, Milwaukee, WI 53211.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoHealing Skills for Medical Practice Larry R. Churchill and David Schenck The Importance of Healing Skills in the Medical Home Concept Edward J. Volpintesta Metrics 3 March 2009Volume 150, Issue 5Page: 360-361KeywordsConflicts of interest ePublished: 3 March 2009 Issue Published: 3 March 2009 Copyright & PermissionsCopyright © 2009 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Effect of afatinib alone and in combination with trastuzumab in HER2-positive breast cancer cell lines.
Authors: Alexandra Canonici, Kasper Pedersen, Brigid Browne, Martina McDermott, Naomi Walsh, John Crown, Norma O'Donovan
Journal: Journal of Clinical Oncology (2013)

632 Background: Trastuzumab and lapatinib have been shown to significantly improve the prognosis for HER2 positive breast cancer patients. However, resistance is a significant clinical problem. The aim of this study is to assess the activity of afatinib, an irreversible pan-HER tyrosine kinase inhibitor, in HER2 overexpressing breast cancer cell lines, including trastuzumab and/or lapatinib resistant cells. Methods: Using proliferation assays, the effect of afatinib was assessed alone and in combination with trastuzumab in HER2 positive cell lines. The effect of afatinib on HER2, Erk and Akt was determined by immunoblotting. Results: The eight HER2 positive breast cancer cell lines tested, including trastuzumab and/or lapatinib resistant cells, responded to afatinib with IC 50 values ranging from 5 to 80 nM. The combination of afatinib and trastuzumab was additive in four trastuzumab sensitive cell lines and one model of acquired trastuzumab resistant HER2 positive breast cancer. In the remaining three trastuzumab and/or lapatinib resistant cell lines, combined treatment with trastuzumab and afatinib showed no enhancement compared to afatinib alone. Finally, afatinib decreased the phosphorylation of HER2 and Erk in all cell lines tested. Conclusions: Our results suggest that afatinib has activity in HER2 positive breast cancer, including trastuzumab and/or lapatinib resistant breast cancer. We also demonstrate that afatinib in combination with trastuzumab may be more effective than either agent alone in trastuzumab sensitive breast cancer. [Table: see text]
Physiologie et physiopathologie du système réticulo-endothélial
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AUSTRALIA
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SYPHILOPHOBIA.
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Care of women infected with the human immunodeficiency virus
Authors: H. L. Minkoff
Journal: JAMA (1991)

<h3>Objective.</h3> —To review current knowledge regarding human immunodeficiency virus (HIV) infection in women and to derive from that data standards of care. <h3>Data Sources.</h3> —Selective review of pertinent articles addressing cervical disease, pelvic inflammatory disease, sexually transmitted diseases, contraception, and pregnancy in HIV-infected women. A computer-assisted search was used to identify relevant articles on pharmacokinetics of drugs in women and oral contraceptive—drug interactions. <h3>Data Extraction.</h3> —Pertinent data were abstracted from case-control, cohort studies, clinical trials, and pharmacokinetic studies. <h3>Data Synthesis.</h3> —Few studies have been performed to define the clinical course of HIV infection in women. Gender-specific manifestations, such as cervical neoplasia, pelvic inflammatory disease, and vaginal moniliasis, appear to pursue a more aggressive course in HIV-infected women. Little is known about the pharmacokinetics of drugs for HIV and related infections. Oral contraceptives may alter the metabolism of some drugs used in HIV-infected women. An approach to the routine treatment of HIV-infected women is summarized. <h3>Conclusions.</h3> —Little is currently known regarding the natural course of HIV infection in women. Women infected with HIV should be followed up frequently with specific attention paid to the reproductive system. Additional studies should be conducted to determine the impact of HIV on gender-specific diseases. (<i>JAMA</i>. 1991;266:2253-2258)
Clinical Summaries
Journal: Circulation (2010)

Results From the REPLACE RegistryCardiac implantable electronic device use is increasing worldwide.Improvements in medical therapy will result in many patients requiring subsequent procedures for generator replacement or "upgrades" to multilead systems.Although data from retrospective series have been available, REPLACE is the first prospective multicenter trial to examine complications related to generator replacement.The 2 patient populations studied included patients who needed only a generator replacement and those who required a lead addition or revision for advanced therapy.This study examined a broad range of major and minor complications.Major complications with planned generator replacements alone were modest; however, when a transvenous lead addition or revision was combined with a generator replacement, the risk was markedly higher, especially for left ventricular leads.Our results support the use and development of devices with long battery life to minimize the lifetime surgical risk for a patient.The choice of device for each patient must be carefully considered.Mitigation of lead-related risks is also important.Using the fewest leads necessary for the clinical need of the patient is critical.The risk associated with upgrade procedures is concerning and favors performing indicated complex procedures before the development of advanced end-stage medical and cardiac disease, situations in which the risk may be prohibitive.Finally, our results provide insight into procedural outcomes for the next phase of life for patients who receive cardiac implantable electronic devices and a more robust analysis that can be used to establish a benchmark for comparative performance in this time of healthcare reform.See p 1553.
Rates of Cesarean Delivery—United States, 1991
Journal: JAMA (1993)

Cesarean deliveries have accounted for nearly 1 million of the approximately 4 million annual deliveries in the United States since 1986 (Table 1). The cesarean rate in the United States is the third highest among 21 reporting countries, exceeded only by Brazil and Puerto Rico (1). This report presents data on cesarean deliveries from CDC's National Hospital Discharge Survey (NHDS) for 1991 and compares these data with previous years.
Efficacy and safety of GLS4/ritonavir combined with entecavir in HBeAg-positive patients with chronic hepatitis B: interim results from phase 2b, multi-center study
Authors: Mingyuan Zhang, Jiming Zhang, Youwen Tan, Yongning Xin, Haibing Gao, Sujun Zheng, Yongxiang Yi, Jie Zhang, Chao Wu, Yingren Zhao, Zhenjing Jin, Zhiliang Gao, Xiaorong Mao, Maorong Wang, Peng Hu, Huiying Rao, Zhansheng Jia, Jinlin Hou, Liang Chen, Xingxiang Yang, Jiajie Lu, Tao Han, Yongping Chen, Qin Ning, Dongliang Yang, Jia Shang, Jianning Jiang, Qingwei He, Yunfu Chen, Qingyun Ren, Lin Luo, Qinghong Zhou, Yingjun Zhang, Fei Kong, Yu Pan, Yanhua Ding, Junqi Niu
Journal: Journal of Hepatology (2020)
Phase I study of the safety and activity of formulated IL-12 plasmid administered intraperitoneally in combination with neoadjuvant chemotherapy in patients with newly diagnosed advanced stage ovarian cancer.
Authors: Premal H. Thaker, William Hampton Bradley, Charles A. Leath, Camille Catherine Gunderson, Nicholas Borys, Khursheed Anwer, Lauren Musso, Ronald David Alvarez
Journal: Journal of Clinical Oncology (2017)

5568 Background: This study evaluated weekly intraperitoneal (IP) GEN-1, an IL-12 plasmid formulated with polyethyleneglycol-polyethyleneimine cholesterol lipopolymer, with intravenous (IV) weekly taxane (T) and carboplatinum (C) every 3 weeks in epithelial ovarian, fallopian tube or primary peritoneal cancer (EOC) patients undergoing neoadjuvant therapy (NAC). The primary objective was to evaluate the tolerability and safety of GEN-1 with NAC. Secondary objectives included objective clinical response and pathological response at interval debulking surgery (IDB). Methods: Newly diagnosed advanced stage EOC patients being treated with NAC were eligible. The trial utilized a 3+3 design with GEN-1 IP dose levels of 36 mg/m 2 , 47 mg/m 2 , 61 mg/m 2 , and 79 mg/m 2 weekly for 8 treatments with concurrent IV T/C. Dose-limiting toxicity (DLT) was based on the first 4 doses of GEN-1 administered. Results: To date, 13 patients have been treated on-study with 12 patients receiving all 8 treatments of IP GEN-1 with no DLTs. The most common related toxicities were Gr 1 nausea, vomiting, abdominal pain and fatigue. One patient experienced Gr 2 fevers associated with GEN-1 but responded to acetaminophen and fluids. One patient did not undergo IDB while on-study due to a cancer related pulmonary embolism and severe deconditioning. This patient has since improved and will have IDB. Conclusions: Adding GEN-1 to neoadjuvant T/C is safe and appears to be active in EOC patients. We are reporting the interim findings; final results with translational data to be presented. Clinical trial information: NCT02480374. [Table: see text]
Establishment and immunological characterization of cultured human gallbladder epithelial cells
Authors: M Auth
Journal: Hepatology (1993)

Biliary epithelial cells are a primary site of damage in liver allograft rejection and in immunologically mediated diseases such as primary biliary cirrhosis. Human leukocyte antigens and adhesion molecules on the biliary epithelium are associated with T-lymphocytic binding, recognition and destruction. To investigate relevant cellular immunological mechanisms under standard conditions, we have established an in vitro model using human gallbladder epithelial cells. Although not directly affected in these aberrations, gallbladder epithelial cells are excellent objects for immunological investigations. More than 108 highly purified cells were isolated and cultured longer than 6 wk in confluent monolayers. Cell growth was routinely established on uncoated plastic culture dishes, and serum-free media could be applied for immunological experiments. Cell characterization was performed by means of specific monoclonal antibodies typical for biliary epithelial cells. Cytokeratins 1 through 8, 18 and 19 and human epithelial cell antibody 125 always showed strong positive staining. Antigen patterns were examined before and after treatment with interferon-γ by use of immunohistochemical staining methods. Untreated human gallbladder epithelial cells expressed human leukocyte class I antigens but few or no class II antigens. After stimulation with interferon-γ induction of human leukocyte antigen-DR, -DP and -DQ was detected. In addition, intercellular adhesion molecule 1 was induced on these gallbladder epithelial cells. Therefore an immunological competence similar to that of biliary epithelial cells could be demonstrated. In vitro cell cultures of gallbladder epithelial cells offer a promising tool for subsequent investigations concerning intrahepatic biliary epithelial cells and their interactions with cells of the immune system. (HEPATOLOGY 1993;18:546–555.)
Biology of Senescent Liver Peroxisomes: Role in Hepatocellular Aging and Disease
Authors: Jihan Youssef, Mostafa Badr
Journal: Environmental Health Perspectives (1999)

Despite rising interest in the health problems of the elderly, information on senescence-related alterations in essential metabolic pathways and their responses to various chemicals is scarce. Although peroxisomal pathways are involved in a multitude of cellular functions, little attention has been given to the potential relationship between senescence of these organelles and the process of aging and disease. Although the prevailing experimental evidence points to a decline in liver peroxisomal enzyme activities and a muted response to peroxisome-proliferating chemicals in aged animals, it is also evident that aged animals are more susceptible, in comparison to their young counterparts, to the hepatocarcinogenic effects of these chemicals. Furthermore, little is known about extraperoxisomal effects of peroxisome proliferators in aged animals. This review evaluates published studies on the impact of aging on basal hepatic peroxisomal metabolism, response to peroxisome proliferators, and changes in signal transduction pathways involved in these processes, with the aim of stimulating research efforts in this important area. The potential intricate relationship among senescent peroxisomes, aged hepatocytes, and health are also discussed.
Response to Letter Regarding Article, “Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention: Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel Study”
Authors: Marco Valgimigli, Gianluca Campo, Roberto Ferrari, Nicoletta de Cesare, Emanuele Meliga, Pascal Vranckx, Alessandro Furgieri, Dominick J. Angiolillo, Manel Sabatè, Salvatore Brugaletta, Martial Hamon, Alessandra Repetto, Salvatore Colangelo, Giovanni Parrinello, Gianfranco Percoco
Journal: Circulation (2010)
JAMA Internal Medicine
Authors: Phil Fontanarosa, Annette Flanagin, Brenda Gregoline, Lauren Fischer, John Mcfadden, Karen Boyd, Rochelle Lodder, Sam Wilder, Diane Cannon, Connie Manno, Fred Marshall, Laura Copyreaders, Catherine Adamczyk, Stephanie Alden, Jan Beckmeyer, Mary Clavey, Paula Coerver-Connolly, Roya Glitman, Laura Khatiblou, Donna King, Caroline Thordsen, Wanda Assistant, Larry Bryant, Monica Mungle, Elaine Williams, Lenette Gardner-Gullens, Fanny Brown, Paul Frank, Peter Kim, Rachell Lozano, Michaela Mark, Kathryn Muskovich, Elizabeth Scientifi, Michael Berkwits, Michelle Kurzynski, Eric Butkus, Will English, Craig Mccaff Rey, Reuben Rios, Ronna Henry, Joshua Bird, Karen Bucher, Samantha Welker, David Song, Deputy Livingston, Thomas Cole, Marla Hall, Deanna Willis, Yolanda Davis, Joseph Thornton, Preeti Malani, Deanna Bellandi, Jim Periodical, Thomas Easley, Brian Shields, Monica Smith, Jeff Ery, J Bonistalli, Kathy Russell, Mirna Monal, Stacey Mchugh, Tim Melroy, Marketing Thornbury, Tricia Castellano Classifi, Thalia Moss, Mike Harvey, Susan Henning, Saskia Bolore, Gretchen Linder, Brian Mccartney, David Baum, Rebecca Haas, Christine Hearne, Irma Lara, Ron Marketing, Paul Gee, Matt Herron, Elizabeth Solaro, Geoff Rey, Rick Bell, Lindsay Dawson, Michael Mcgraw, Romando Rossini, Stacy Staff, Millette Jackson-Bates, Karen Adams-Taylor, Karl Elvin, Jaye Mize, Sean O'donnell, Sue Managers, David Antos, Chris Borden, Debbie Camp, Lydia Cruz, Scott Curl, Diane Darnell, Colleen Kelly, Chris Meyer, Annemarie Neff, J Neff, Sean Ohlson, Phil O'leary, Bill Pedone, Susan Price, Denise Steinhauser, Joe Advertising, Production Services, Kim Boler, Rhonda Brown, Timothy Burke, Daniel Degroot, Jordynn Farrar, Euwanaha Joiner-Smith, Cindy Rendlen, Ellen Yoshihara, Circulation Services, Julie Burton, Dexter Golden, Erin Hinchcliff, Maria Nienhaus, Noemi Rivera, Geneine Van, Someren Composition, New Media, Gail Barrett, Regina Brownlee, Amanda Camino, Brenda Chandler-Grayer, Emily Dunn, Amy Evers, Teri Hutchison, Mary Kuranda, Joshua Lampinen, Nathan Mitre, Patricia Panek, La Son, Diggs Sledge, George Thomson Graphics, Joe Amft, Maria Duda, Fred Furtner, Carolyn Hall, Maria Kowalkowski, Proofreading Carol, Joy Farrell, Daniel James, Judith Literskis, Teresa Omiotek, James Madara, Bernard Hengesbaugh, Zachary Goldberger, Nora Goldschlager, San Francisco, Gregory Marcus, Elsayed Soliman, Carolina Cme, Jeff Rey Tabas, Fiona Clement, Rebecca Larson, Deborah Grady, Howard Bauchner, Rita Redberg, Rosemary Gibson, Shannon Brownlee, Tanner Caverly, Ann Arbor, Brandon Combs, Christopher Moriates, Neel Shah, Robert Steinbrook, New Haven, James Colbert, David Brown, St Louis, Lara Goitein, Santa Fe, New Mexico, Chi-Yuan Hsu, Grace Lin, Mary Mcdermott, C Noel, Bairey Merz, Los Angeles, Samia California, Judith Mora, Kathryn Prochaska, Mary Rexrode, New Tinetti, Nicolas Rodondi, Iona Heath, Mitchell Katz, Patrick California, John Boscardin, John Neuhaus, Kenneth Covinsky, Joseph Ross, Blake Charlton, Rachel Stern, Charlotte Dudley, Kate Denevan
Journal: JAMA Internal Medicine (2015)